Page 172 - 16_Atti_SNO_2022_flip

Proceedings SNO “LXI Congresso Nazionale SNO”

Magyari M. Incidence of MS has increased markedly over six 7. Bsteh G, Hegen H, Riedl K, Altmann P, Auer M, Berek K, Di
decades in Denmark particularly with late onset and in Pauli F, Ehling R, Kornek B, Monschein T, Rinner W,
women. Neurology 2018; 90 (22): e1954-e1963. Schmied C, Wurth S, Zebenholzer K, Zinganell A, Zrzavy T,
Zulehner G, Deisenhammer F, Rommer P, Leutmezer F,
4. Marrie RA. Comorbidity in multiple sclerosis: implications
Berger T. Quantifying the risk of disease reactivation after in-
for patient care. Nat Rev Neurol 2017; 13 (6): 375-382.
terferon and glatiramer acetate discontinuation in multiple
5. Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood sclerosis: The VIAADISC score. Eur J Neurol 2021; 28 (5):
M, Bielekova B. Meta-analysis of the age-dependent efficacy 1609-1616.
of multiple sclerosis treatments. Front Neurol 2017; 8: 577.
8. Prosperini L, Haggiag S, Tortorella C, Galgani S, Gasperini C.
6. Jakimovski D, Eckert SP, Zivadinov R, Weinstock-Guttman B. Age-related adverse events of disease-modifying treatments
Considering patient age when treating multiple sclerosis across for multiple sclerosis: a meta-regression. Mult Scler 2021; 27
the adult lifespan. Expert Rev Neurother 2021; 21 (3): 353-364. (9): 1391-1402.

- 170 -